ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2017
A New Preclinical Paradigm for Testing Anti-Aging Therapeutics.
Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 29 citations in OpenAlex.
- Advances in anti-aging Drug research leveraging multi-omics and artificial intelligence.Frontiers in aging · 2026Review
- The effect of bempedoic acid on histopathologic changes associated with natural aging in rat lungs.BMC pulmonary medicine · 2025Article
- Older-aged C57BL/6 mice fed a diet high in saturated fat and sucrose for ten months show decreased resilience to aging.Aging pathobiology and therapeutics · 2023Article
- Cellular senescence: a key therapeutic target in aging and diseases.The Journal of clinical investigation · 2022Review
- Short term treatment with a cocktail of rapamycin, acarbose and phenylbutyrate delays aging phenotypes in mice.Scientific reports · 2022Article
- Heterochronic parabiosis: a valuable tool to investigate cellular senescence and other hallmarks of aging.Aging · 2022Article
- Automated, high-dimensional evaluation of physiological aging and resilience in outbred mice.eLife · 2022Article
- Pharmaceutical interventions to slow human aging. Are we ready for cocktails?Aging pathobiology and therapeutics · 2022Article
- Oklahoma Nathan Shock Aging Center - assessing the basic biology of aging from genetics to protein and function.GeroScience · 2021Article
- Einstein-Nathan Shock Center: translating the hallmarks of aging to extend human health span.GeroScience · 2021Article
- The antidiabetic drug acarbose suppresses age-related lesions in C57BL/6 mice in an organ dependent manner.Aging pathobiology and therapeutics · 2021Article
- The geropathology of organ-specific aging.Journal of translational science · 2021Article
- Acarbose has sex-dependent and -independent effects on age-related physical function, cardiac health, and lipid biology.JCI insight · 2020Article
- Heterochronic parabiosis regulates the extent of cellular senescence in multiple tissues.GeroScience · 2020Article
- ATM is a key driver of NF-κB-dependent DNA-damage-induced senescence, stem cell dysfunction and aging.Aging · 2020Article
- Development of a Geropathology Grading Platform for nonhuman primates.Aging pathobiology and therapeutics · 2020Article
- Article
- Fisetin is a senotherapeutic that extends health and lifespan.EBioMedicine · 2018Article
- Circulating levels of monocyte chemoattractant protein-1 as a potential measure of biological age in mice and frailty in humans.Aging cell · 2018Article
- Modeling Alzheimer's disease in progeria mice. An age-related concept.Pathobiology of aging & age related diseases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
Testing drugs for anti-aging effects has historically been conducted in mouse life-span studies, but are costly and time consuming, and more importantly, difficult to recapitulate in humans. In addition, life-span studies in mice are not well suited to testing drug combinations that target multiple factors involved in aging. Additional paradigms for testing therapeutics aimed at slowing aging are needed. A new paradigm, designated as the Geropathology Grading Platform (GGP), is based on a standardized set of guidelines developed to detect the presence or absence of low-impact histopathological lesions and to determine the level of severity of high-impact lesions in organs from aged mice. The GGP generates a numerical score for each age-related lesion in an organ, summed for total lesions, and averaged over multiple mice to obtain a composite lesion score (CLS). Preliminary studies show that the platform generates CLSs that increase with the age of mice in an organ-dependent manner. The CLSs are sensitive enough to detect changes elicited by interventions that extend mouse life span, and thus help validate the GGP as a novel tool to measure biological aging. While currently optimized for mice, the GGP could be adapted to any preclinical animal model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.